BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Pemetrexed: trial readouts and FDA decisions

12 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 18 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Akeso, Innovent Biologics (Suzhou) Co. Ltd., CSPC Megalith Biopharmaceutical Co.,Ltd., Lantern Pharma Inc., Eikon Therapeutics, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell LungResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancerrecruiting170
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-12 est.P2Lantern Pharma Inc. LTRNNCT05456256 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaAdenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lungrecruiting90
2026-12 est.P2Eikon Therapeutics EIKNNCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNSCLCactive not recruiting70
2026-12 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients WiNon-Small Cell Lung Canceractive not recruiting432
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCNSCLCrecruiting808
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12-10 est.P3Boehringer IngelheimNCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With StandarLung Cancer, Non-squamous, Non-small Cellactive not recruiting428
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-11 est.P3AstraZeneca AZNNCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGMetastatic Non-small Cell Lung Canceractive not recruiting768
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09-22P3Takeda TAKNCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)completed354
2026-09-17P2Arcus Biosciences, Inc. RCUSNCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNon Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancompleted169
2026-08-31 est.P3mAbxience Research S.L.NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung CancerNon Squamous Non Small Cell Lung Canceractive not recruiting726
2026-08-30 est.P2TJ Biopharma Co., Ltd.NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated LocaNon Small Cell Lung Canceractive not recruiting150
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-08-17P3AstraZeneca AZNNCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Metastatic Non-small Cell Lung Canceractive not recruiting895
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)Non-small Cell Lung Canceractive not recruiting432
2026-07-31P3Hoffmann-La RocheNCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancercompleted11
2026-07-30 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)EGFR-mutated Locally Advanced or Metastatic NSCLCrecruiting380
2026-07-13P1/P2GlaxoSmithKlineNCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker PositroLung Cancer, Non-Small Cellterminated2
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341
2026-07 est.P2AkesoNCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting265
2026-06-30 est.P1/P2AkesoNCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerAdvanced Non-small-cell Lung Canceractive not recruiting233
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06-09P3AstraZeneca AZNNCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small CLocally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting454

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.